Pacifor® Oral Solution

Oral solution.

Tranquilizer.

Each 100 mL of solution contains:
Acepromazine Maleate…………… 1.35 g
(Equivalent to 1 g of Acepromazine base)
Excipients c.s.p………………….100 mL

Pacifor® Oral solution, it is indicated as a sedative agent (tranquilizer) for dogs and cats.

Oral.

• Dogs: 1 to 2 drops per kg of body weight (0.5 to 1 mg/kg).
• Cats: 2 to 3 drops per kg of body weight (1 to 1.5 mg/kg).

The calming effect takes about 30 to 40 minutes. Place the animal in a quiet environment. The duration of the effect is 6 to 12 hours.

Dogs and cats.

• Do not administer to pregnant or lactating females.
• Do not use in animals subjected to examinations such as myelography.
• Do not use in animals with a history of seizures.
• Do not administer in animals with hypovolemia or shock, due to their hypotensive effects.
• Do not administer in animals with coagulopathies or thrombocytopenia, due to their effects on platelet aggregation.
• Do not administer in animals with tetanus or strychnine poisoning, due to the effects on the extrapyramidal system.
• Do not administer within one month of deworming with organophosphate agents as their effects may be enhanced.

• Acepromazine generates vasodilation-mediated hypotension, which may last for a few hours and should be considered during use. In healthy animals, this hypotension is usually mild, but it can be accentuated in anesthetized, weakened, or hypovolemic patients.
• Unusual cardiovascular collapse of variable severity (secondary to bradycardia and hypotension) has been reported in some dogs, especially in brachycephalic breeds.
• Acepromazine causes significant intraoperative hypothermia because it depresses the hypothalamic thermoregulatory center and causes cutaneous vasodilation. This effect lasts for a few hours.
• Acepromazine causes nictitating membrane prolapse, which lasts for a few hours while its effect is maintained.
• Acepromazine may decrease hematocrit for several hours, as a result of splenic congestion following blockade of α1-adrenergic receptors, which may be important in anemic animals. This effect is transient and is restored after several hours.
• Acepromazine decreases platelet aggregation transiently without affecting clotting times.
• Occasionally, acepromazine may generate contradictory clinical signs of aggressiveness and generalized stimulation of the central nervous system. These reactions are rare and transient in nature and usually do not last longer than 48 hours.

• Following administration of acepromazine, lower doses of general anesthetics are required.
• Use with caution and at the lowest recommended dose in animals with hepatic dysfunction, heart disease, and general weakness.
• Use with caution in very young or debilitated animals, due to its effects on thermoregulation.
• Use with caution in geriatric patients, as very low doses have been associated with prolonged effects of the drug.
• Acepromazine does not possess analgesic effects, so appropriate measures should be taken to control pain in treated animals.
• Use with caution in brachycephalic dogs (Boxers, Pekingese, etc.) or Persian cats, as they may be very sensitive to the bradycardic effects of Acepromazine.
• Use with caution in dogs with MDR1 mutations (Collies, Australian Shepherds, among others), as they may develop deeper sedation that persists longer than usual.
• Giant breeds and Greyhounds can be extremely sensitive to the drug, while terrier breeds are somewhat resistant to its effects.
• Acepromazine should be used with caution as a containment agent in aggressive dogs, as it may cause animals to be more prone to startle and react to noises or other sensory stimuli.
• Atropine can be used in conjunction with Acepromazine to help block its bradycardic effects.
• During sedation with Acepromazine it is recommended to use ocular lubricants or artificial tears as corneal protectors, due to the reduction in tear production.
• A higher dose does not accelerate the onset of sedation, it only lengthens the sedative effect.
• Once it has been administered, it is important to leave the animal in a quiet place for about 15 minutes or until the sedative effects are achieved.
• After administration, patients should not be exposed to extreme temperature fluctuations for at least 8 hours.
• Administration in conjunction with other respiratory or central nervous system depressants may exacerbate respiratory depression.
• Keep out of reach of children and pets.

• Combinations of antidiarrheals (e.g., kaolin-pectin, mixtures with bismuth subsalicylate) and antacids may reduce gastrointestinal absorption of orally administered phenothiazines.
• Central Nervous System (CNS) depressant agents (barbiturates, narcotics, anesthetics, etc.), may exacerbate CNS depression if used in conjunction with acepromazine.
• Epinephrine: Phenothiazines block alpha-adrenergic receptors; concomitant administration with epinephrine may lead to beta activity causing vasodilation and increased heart rate.
• Opioids: May improve the hypotensive effects of Acepromazine. Doses of Acepromazine are usually reduced when used with an opioid.
• Organophosphate agents: Acepromazine should not be administered within one month of deworming with these agents as their effects may be potentiated.
• Phenytoin: Its metabolism may decrease if given simultaneously with phenothiazines.
• Procaine: Activity can be enhanced by phenothiazines.
• Propranolol: Co-administration of acepromazine and propanolol may lead to serum elevation of both drugs.
• Quinidine: With phenothiazines it can cause additive cardiac depression.
• Vasoconstrictors, such as phenylephrine, antagonize the hypotensive effects of phenothiazines.

• In the case of ocular exposure, the eyes should be irrigated with plenty of water. If irritation exists and persists, the patient should be evaluated by a physician.
• In the case of dermal exposure, contaminated clothing should be removed or the exposed area should be washed thoroughly with water. If irritation is present and persists, the patient should be evaluated by a physician.
• In case of accidental ingestion, the mouth should be washed. If large amounts have been swallowed, immediate medical attention should be sought.

• Dispose of unused product residues in their original packaging. Do not dispose of empty containers or containers with product residues in rivers, lakes or streams.
• Do not reuse the packaging.
• Dispose of waste of this product with caution along with household waste.

Store between 15 and 30º C, away from light. Once opened, use within 12 weeks. Discard the unused product after that period of time.

Chile: Sale by prescription to the Veterinary Doctor.
Peru: Under prescription restricted.

Chile: Reg. SAG N°: 516
Bolivia: Reg. SENASAG PUV-F-N° 005517/13
Peru: Reg. SENASA F.62.32.I.0026

Pack with 10 mL

Laboratorio Drag Pharma Chile Invetec S.A.
Lautaro N° 300. Quilicura. Santiago. Chile.